Teva Pharmaceutical Advances Neuroscience Pipeline With Strong AUSTEDO Growth and New Acquisition
Source: Streetwise Reports  (6/17/26)
Teva Pharmaceutical Industries reports robust first-quarter revenue growth from AUSTEDO and specialty products while closing the Emalex acquisition and advancing multiple late-stage programs in neuroscience, immunology, and respiratory diseases for retail investors. More >

A New Pharma Giant Goes Public as a Sector Leader Makes Moves in Neuroscience
Source: Streetwise Reports  (6/16/26)
Apotex Health Corp. (APTX:TSX) raised approximately CA$1.3 billion in its IPO while Teva Pharmaceutical Industries Ltd. (TEVA:NYSE) reported new AUSTEDO data and added a late-stage Tourette syndrome asset. More >

Nuvalent Acquisition by GSK Highlights Growing Opportunities in Targeted Oncology Therapies
Source: Streetwise Reports  (6/16/26)
Explore how the pending GSK acquisition of Nuvalent at a premium underscores sector momentum in precision oncology, with key pipeline catalysts and market trends for retail investors to consider. More >

Analysts Cut Biopharma Co. to Neutral After Pending US$10.6B Deal
Source: Streetwise Reports  (6/15/26)
Analysts downgrade Nuvalent Inc (NUVL:NASDAQ) to "Neutral" after GSK's US$10.6B all-cash buyout offer at US$124/share, calling the deal favorable but a competing bid unlikely. More >

MindBio Therapeutics Positions Voice AI Kiosks for Growth in Workplace Safety Markets
Source: Streetwise Reports  (6/13/26)
MindBio Therapeutics advances prototype Edge AI kiosks for non-invasive intoxication and fatigue detection, targeting high-growth opportunities in mining, aviation, and construction sectors amid expanding biotech and AI markets. More >

Oculis Holding AG Pioneers Genotype-Based Precision Approach to Dry Eye Disease Treatment
Source: Streetwise Reports  (6/13/26)
Oculis Holding AG launches the PREDICT-1 trial for licaminlimab, targeting patients with a specific TNFR1 genotype to address unmet needs in the large dry eye disease market. More >

MindBio Therapeutics Positions Voice AI Technology for Growth in Safety-Critical Sectors
Source: Streetwise Reports  (6/12/26)
Explore how MindBio Therapeutics is advancing voice-based AI detection for intoxication across mining, aviation, and other industries, backed by strong market trends and analyst targets. More >

MindBio Therapeutics Advances AI Voice Tech for Workplace Safety in Growing Biotech and AI Detector Markets
Source: Streetwise Reports  (6/12/26)
MindBio Therapeutics delivers first prototype Edge AI kiosks for non-invasive intoxication and fatigue detection, positioning the company in high-growth sectors including mining, aviation, and construction, while analysts highlight significant upside potential. More >

Biopharma Co. Trials Precision Medicine Breakthrough for Dry Eye Disease. Gets Positive Results
Source: Streetwise Reports  (6/12/26)
Oculis Holding AG (OCS:NASDAQ; OCS:XICE) launches PREDICT-1, a genotype-based trial for licaminlimab, targeting 10M moderate-to-severe dry eye patients. More >

Biotech Firm Launches Massive AI Safety Solution for Zero-Tolerance Industries
Source: Streetwise Reports  (6/11/26)
MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) delivers first Edge AI intoxication detection kiosk prototypes for mining, aviation, and construction safety screening. More >

Biotech Firm Deploys Revolutionary Intox AI, Unlocking Billion-Dollar Industrial Safety Opportunity
Source: Streetwise Reports  (6/10/26)
MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) launches Intox AI, detecting intoxication via voice, targeting mining and aviation in a US$2.06B market. More >

ORIC Pharmaceuticals Positions for Growth in Expanding Oncology Market
Source: Streetwise Reports  (6/10/26)
Explore how ORIC Pharmaceuticals is advancing its oncology pipeline with key catalysts ahead, amid rising global demand for innovative cancer treatments and strong analyst support. More >

Grey Matters Health Positions for Growth in Expanding Alzheimer's Diagnostics Market
Source: Streetwise Reports  (6/10/26)
Grey Matters Health advances its Alzheimer's neuroimaging strategy with fresh financing and plans for the first U.S. brain-specific PET clinic, capitalizing on rising demand for early detection tools. More >

Alzheimer's Diagnostic Clinic Initiative Moves Forward After Financing Close
Source: Streetwise Reports  (6/9/26)
Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB) closed the first CA$500,000 tranche of a financing that the company said will support its Alzheimer's disease program and planned U.S. brain-specific neuroimaging clinic. More >

Clinical-Stage Biopharma Co. Issues New Inducement Stock Options for Growth
Source: Streetwise Reports  (6/8/26)
ORIC Pharmaceuticals Inc. (ORIC:NASDAQ) granted 34,800 stock options and 5,900 restricted stock units to new employees as analysts issue "Buy" ratings for the year ahead. More >

Cancer Drug Developer Shifts 70% of Spending to Research as AI Pipeline Progresses
Source: Streetwise Reports  (6/5/26)
Rakovina Therapeutics (TSX.V: RKV) reported lower net losses, reduced administrative spending, debt restructuring, financing activity, and progress across its AI-driven oncology pipeline in Q1 2026. More >

From Healthcare IT Vendor to AI-Driven Holding Company
Source: Mike Sheikh  (6/5/26)
Healthcare Triangle Inc.'s (HCTI:NASDAQ) Spanish AI acquisition delivers US$34M in revenue and a near-US$40M agentic AI run rate, while shares still trade at just 1x cash. More >

California Pharma Co. Tests Breakthrough Cancer Drug, Cuts Death Risk 60%
Source: Streetwise Reports  (6/4/26)
Revolution Medicines Inc.'s (RVMD:NASDAQ) daraxonrasib treats pancreatic cancer patients, doubling median survival. Analysts rate it a "Buy" with targets up to US$263. More >

US Biotech Co. Targets Muscular Dystrophy with First-In-Class Drug
Source: Streetwise Reports  (6/1/26)
Capricor Therapeutics Inc.'s (CAPR:NASDAQ) Deramiocel targets FDA approval by August 2026, with analysts issuing Buy ratings and price targets as high as US$60. More >

New Alzheimer's Imaging Push Expands as Financing Terms Get Investor-Friendly
Source: Streetwise Reports  (5/29/26)
Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB) amended warrant terms tied to its CA$1 million private placement as it advances plans for a U.S. brain-specific neuroimaging clinic focused on Alzheimer's diagnostics. More >

Biopharma Company Reveals High-Impact SCI Recovery Gains
Source: Streetwise Reports  (5/28/26)
NervGen Pharma Corp. (NGEN:TSX.V; NGENF:OTCQX) reports 100% responder rates for NVG-291 in spinal cord injury trials, strengthening hopes for major recovery breakthroughs. More >

200 Brain PET Scans, 162 Alzheimer's Drugs: A Diagnostic Push Takes Shape
Source: Streetwise Reports  (5/22/26)
Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB) signed an LOI tied to a minimum of 200 brain PET scans for an Alzheimer's clinical trial while expanding its NovaScan neuroimaging strategy. More >

Cleantech Co. Wins PFAS Deal, Engineering Pact, Ships Clyra
Source: Richard Ryan  (5/21/26)
BioLargo (BLGO:OTCQX) shipped Clyra's first stocking order, signed Aquatech PFAS MOU, and won a US$1.2M engineering contract for a minerals processing facility, according to an Oak Ridge Financial research note More >

Lexington, MA Biotech Pushes DMD Phase 2 Start to 3Q26 on Regulatory Hurdles
Source: Dr. Yun Zhong  (5/20/26)
Keros Therapeutics (KROS:NASDAQ) disclosed that initiation of its Phase 2 rinvatercept study in Duchenne muscular dystrophy will slip from 2Q26 to 3Q26 due to procedural regulatory delays, according to a Wedbush research note. More >

Lexington, MA Biopharma Co. Reports Q1 2026 Financials, Makes R&D Plans
Source: Streetwise Reports  (5/20/26)
Keros Therapeutics Inc. (KROS:NASDAQ) lowered research spending & reported funding through 2028 as analysts monitor upcoming trial catalysts for ALS & Muscular Dystrophy drugs. More >